Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 May;8(3):190-5.
doi: 10.1097/COH.0b013e32835fc68a.

Overcoming pharmacologic sanctuaries

Affiliations
Review

Overcoming pharmacologic sanctuaries

Theodore J Cory et al. Curr Opin HIV AIDS. 2013 May.

Abstract

Purpose of review: Current antiretroviral treatment regimens represent significant improvements in the management of HIV-1 infection; however, these regimens have not achieved a functional or sterilizing cure. One barrier to achieving a cure may be suboptimal antiretroviral concentrations in sanctuary sites throughout the body, including the central nervous system, gut-associated lymphoid tissue, lymph nodes, and tissue macrophages. This review will focus on the problems associated with achieving effective concentrations in these restricted sanctuary sites, and potential strategies to overcome these barriers.

Recent findings: Sufficient data exist to conclude that antiretroviral drug distribution is not uniform throughout the body. Low tissue/reservoir concentrations may be associated with viral replication. Multiple means to increase drug concentrations in sanctuary sites are being investigated, including modification of currently utilized drugs, blockade of transporters and enzymes that affect drug metabolism and pharmacokinetics, and local drug administration. Accumulating data suggest these methods increase antiretroviral concentrations in reservoirs of viral replication. No method has yet resulted in the complete clearance of HIV.

Summary: New strategies for increasing antiretroviral concentrations in predominant sites of viral replication may provide more effective means for elimination of viral sanctuaries. Additional research is necessary to optimize antiretroviral tissue distribution in order to inhibit virus replication fully, and avoid resistance and replenishment of viral reservoirs that may persist in the face of antiretroviral therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

Supported in part by grants from the National Institute of Allergy and Infectious Diseases PO1 AI074340 (TWS, MS and CVF) and UO1 AI068636 (CVF).

References

    1. Choi JY, Song YG, Kim YH, et al. Factors associated with HIV-1 proviral DNA loads in patients with undetectable plasma RNA load. J Kor Med Sci. 2009;24:152–154. - PMC - PubMed
    1. Natarajan V, Bosche M, Metcalf JA, et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet. 1999;353:119–120. - PubMed
    1. Verhofstede C, Van Wanzeele F, Reynaerts J, et al. Viral load assay sensitivity and low level viremia in HAART treated HIV patients. J Clin Virol. 2010;47:335–339. - PubMed
    1. Buzón MJ, Codoñer FM, Frost SDW, et al. Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog. 2011;7:e1002314. The variance of HIV DNA sequences in patients was characterized, and suggests that virus reservoirs exist in these patients. - PMC - PubMed
    1. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nature Med. 2000;6:76–81. - PMC - PubMed

Publication types

Substances